You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Financement des régimes fondés sur les données probantes

Les monographies et fiches d’information sur les médicaments et les régimes à l’intention des patients offrent des renseignements sur la posologie et l’administration des traitements contre le cancer.

Elles ne sont fournies qu’à titre indicatif et ne visent pas à remplacer les renseignements posologiques ni les recommandations d’un médecin.

Si vous avez des questions à propos du financement des TS-PBQ, veuillez consulter la Foire aux questions (anglais) de notre site Web.

Découvrez les fiches d’information améliorées sur les régimes à l’intention des patients, élaborées en collaboration avec les conseillers des patients et des familles. Disponible en français.

Regimens

10 Items
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Funding:
Exceptional Access Program
    AFAtinib - For first-line monotherapy treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC), according to specific criteria
May 2019
Cancer Type: Skin, Melanoma     
Intent: Palliative
Funding:
Exceptional Access Program
    daBRAfenib - As monotherapy for the first-line and second-line treatment of patients with BRAF V600 mutation-positive unresectable melanoma or metastatic disease, according to specific criteria
May 2019
Cancer Type: Skin, Melanoma     
Intent: Palliative
Funding:
Exceptional Access Program
    daBRAfenib - In combination with trametinib for the treatment of BRAF V600 mutation-positive, unresectable or metastatic melanoma, according to specific clinical criteria
Exceptional Access Program
    trametinib - In combination with dabrafenib for the treatment of BRAF V600 mutation-positive, unresectable or metastatic melanoma, according to specific clinical criteria
May 2019
Cancer Type: Skin, Melanoma     
Intent: Adjuvant, Curative
Funding:
Exceptional Access Program
    daBRAfenib - For the adjuvant treatment of resected Stage III cutaneous melanoma according to clinical criteria
Exceptional Access Program
    trametinib - For the adjuvant treatment of resected Stage III cutaneous melanoma according to clinical criteria
Updated
Jan 2020
Cancer Type: Hematologic, Leukemia - Chronic Myeloid (CML)     
Intent: Palliative
Funding:
Exceptional Access Program
    daSAtinib - Ph+ CML in the chronic phase, with specific criteria
Exceptional Access Program
    daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria
May 2019
Cancer Type: Hematologic, Leukemia - Acute Lymphoblastic (ALL)     
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    daSAtinib - PH+ ALL, with specific criteria
May 2019
Cancer Type: Hematologic, Leukemia - Chronic Myeloid (CML)     
Intent: Palliative
Funding:
Exceptional Access Program
    niLOtinib - Chronic phase Ph+ CML, with specific criteria
Exceptional Access Program
    niLOtinib - Accelerated phase Ph+ CML with documented resistance or intolerance to imatinib therapy, with specific criteria
Jun 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Funding:
Exceptional Access Program
    Osimertinib - Second-line monotherapy of patients with locally advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer, according to specific criteria
Oct 2018
Cancer Type: Gastrointestinal, Hepatobiliary / Liver / Bile Duct     
Intent: Palliative
Funding:
Exceptional Access Program
    SORAfenib - Advanced hepatocellular carcinoma, with specific criteria
Jun 2019
Cancer Type: Genitourinary, Renal cell / Kidney     
Intent: Palliative
Funding:
Exceptional Access Program
    SORAfenib - Metastatic renal cell carcinoma of clear cell histology as second-line treatment, with specific criteria
Aug 2019